Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Parallel-group, Multiple-dose Study to Evaluate the Pharmacokinetics of Bulevirtide in Participants With Normal and Impaired Hepatic Function

NCT05765344 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05765344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05765344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Parallel-group, Multiple-dose Study to Evaluate the Pharmacokinetics of Bulevirtide in Participants With Normal and Impaired Hepatic Function
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
March 15, 2023
Completion date
January 13, 2025
Enrollment
74 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, hepatic impairment